Compare Comfort Systems USA Inc (FIX) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comfort Systems USA Inc vs Inovio Pharmaceuticals Inc — how do they compare? Comfort Systems USA Inc trades at $1,660 (market cap $61.14B), while Inovio Pharmaceuticals Inc trades at $1.14 (market cap $96.26M). The key difference: Comfort Systems USA Inc is far larger — about 635.2× Inovio Pharmaceuticals Inc's market cap, and Comfort Systems USA Inc pays a 0.15% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| FIX | INO | |
|---|---|---|
Market Cap | $61.14B | $96.26M |
Sector | Technology | Health |
52-Week High | $2.07K | $2.87 |
52-Week Low | $532.14 | $1.05 |
Enterprise Value | $60.42B | $67.27M |
Dividend Yield | 0.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,694.14, down 4.56% amid bearish technical signals, though fundamentals remain strong with Q1 2026 EPS beating estimates at $10.51 versus $6.81 expected. Revenue growth is robust, projected to rise from $9.10B in 2025 to $10.1B in 2026, while net profit margins improve to 12.07%. The company benefits from AI infrastructure demand and a record backlog, though valuation multiples appear elevated with a P/E of 50.14.
Outlook is mixed: analyst consensus is bullish with a $2,100 price target and 55.56% buy ratings, but technical indicators signal near-term pressure. Key risks include execution challenges from rapid growth and premium valuation. The stock offers growth exposure to data center and construction markets, but investors should weigh high multiples against earnings momentum.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
